MetaCap

Bullfrog AI (BFRG) vs MetaVia (MTVA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

MetaVia is the larger company by market cap ($6.8 million vs $6.6 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BFRG-49.82%MTVA-30.82%
+13%-20%-53%
Oct 7, 20261 yearNov 20, 2026
BFRG-44.95%MTVA-28.37%
+4%-22%-47%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BFRG versus MTVA key metrics
MetricBFRGMTVA
Share price$0.3556$1.01
Market cap$6.65M$6.81M
1-day change-8.84%-7.34%
YTD return-59.73%—
1-year return-58.21%—
EPS (TTM)$-0.41$-2.78
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$116.67K—
Net income (latest FY)$-6.50M$-12.97M
Gross margin18.76%—
Operating margin-5652.38%—
Net margin-5569.61%—
52-week high$1.96$13.42
52-week low$0.35$0.966
Distance from 52-week high-81.86%-92.47%
Analyst consensusnonenone
Avg. price target upside—+1813.86%
Average volume5.38M113.44K
Shares outstanding18.69M6.74M
Employees98
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Bullfrog AI

BFRG stock →

Bullfrog AI Holdings, Inc. operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States.

Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees

About MetaVia

MTVA stock →

MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. The company develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in Phase 1 trial for the treatment of obesity.

Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees

BFRG vs MTVA FAQ

Which is bigger, Bullfrog AI or MetaVia?

MetaVia (MTVA) is larger, with a market capitalization of $6.81M compared with $6.65M for Bullfrog AI (BFRG).

Are Bullfrog AI and MetaVia in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons